Table 4. Model Results, Sensitivity Analyses.
| Alternative Values for Acute Stage | Low | High |
|---|---|---|
| Intervention effectiveness (% reduction; baseline: %76) | 10% | 90% |
| ICER (LY) | $50,904.58 | $13,477.29 |
| ICER (QALY) | $83,140.71 | $22,012.00 |
|
| ||
| Device days (% of baseline) | 50% | 150% |
| ICER (LY) | $19,745.43 | $12,419.17 |
| ICER (QALY) | $32,253.18 | $20,286.09 |
|
| ||
| Inpatient mortality attributable to infection (% of baseline) | 50% | 150% |
| ICER (LY) | $10,919.14 | $16,611.52 |
| ICER (QALY) | $17,736.25 | $27,242.51 |
|
| ||
| Inpatient costs attributable to infection (% of baseline) | 50% | 150% |
| ICER (LY) | $20,651.18 | $7,850.29 |
| ICER (QALY) | $33,732.67 | $12,823.06 |
|
| ||
| Intervention Cost (% of baseline) | 50% | 150% |
| ICER (LY) | $11,503.39 | $16,998.08 |
| ICER (QALY) | $18,790.21 | $27,765.52 |
| Alternative Values for Post-Discharge Stage | Low | High |
|---|---|---|
| Discount Rate | 0% | 5% |
| ICER (LY) | $17,255.08 | $12,609.61 |
| ICER(QALY) | $28,908.21 | $25,731.16 |
|
| ||
| Prices | 50% | 150% |
| ICER (LY) | $3,472.27 | $25,029.20 |
| ICER (QALY) | $6,577.81 | $47,414.85 |
|
| ||
| Utilities | 50% | 150% |
| ICER (LY) | $14,250.74 | $14,250.74 |
| ICER (QALY) | $25,028.05 | $29,302.43 |
| Alternative Population Scenarios | ||
|---|---|---|
| Age Cohort | 65 to 69 | 75 to 79 |
| ICER (LY) | $13,512.33 | $14,996.95 |
| ICER (QALY) | $21,048.68 | $24,384.17 |
ICER: Incremental Cost-Effectiveness Ratios, LY: Life Years, QALY: Quality-Adjusted Life Ye ars